PEPTIDES·INDEX
68 peptides285 listingsUpdated…Build My Stack
Library

CJC-1295 / IpamorelinBlend

Classic GH-support blend in one vial.

Peptides·Index rating
2/5Early-Signal
Human data
Safety
Compare prices — from $50.00
Quick factsat a glance
Status
Research / not approved
Developer
Compounded research-peptide blend; vendor-specific
Receptors / target
Not a single target — combines CJC-1295 (GHRH-receptor agonist) and ipamorelin (ghrelin / GHS-R1a agonist); the pair stimulates pituitary GH release through two complementary pathways
FDA-approved?
NO
Prescription available?
NO
Studied for
growth-hormone / IGF-1 secretionbody compositionrecovery & sleepGH-secretagogue pharmacology

Overview

CJC-1295 / Ipamorelin is the classic compounded growth-hormone secretagogue blend, pairing a GHRH analog (CJC-1295) with a selective ghrelin-receptor agonist (ipamorelin). The rationale is that the two stimulate growth-hormone release through complementary pathways, which proponents argue produces a larger, more physiologic GH pulse than either alone. It is sold research-use-only, is not an approved drug, and has no clinical trials as a combination.

Mechanism

CJC-1295 acts as a GHRH-receptor agonist on pituitary somatotrophs, while ipamorelin activates the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). Because GHRH and ghrelin pathways act through different receptors and second messengers, co-stimulation is proposed to be additive or synergistic on pulsatile GH release, which raises hepatic IGF-1. This two-pathway rationale is mechanistically reasonable but the specific combination has not been formally characterized in controlled studies.

Clinical evidence

There are no human trials of the CJC-1295/Ipamorelin blend; evidence comes from each component separately. CJC-1295 has small early-phase human PK/PD studies showing multi-day elevation of GH and IGF-1 in healthy adults; ipamorelin reached a phase 2 trial (for postoperative ileus) that was well tolerated but did not meet its primary endpoint, and its selectivity data are from animals. No controlled human evidence supports the combination for body composition, anti-aging or performance.

Safety profile

The combined-injection safety has not been studied. Both are growth-hormone secretagogues, so the combination can be expected to raise GH/IGF-1 and may affect glucose metabolism and fluid balance; injection-site reactions, flushing and water retention are the most commonly noted component effects. GH-axis stimulants and their analogs are WADA-prohibited (S2), so this blend is banned in sport. Neither component is FDA-approved, and long-term human safety is unestablished. Research-use only; nothing here is therapeutic or dosing guidance.

Timelinecommonly reported
  1. Per dose (acute)

    A combined GH pulse follows dosing; CJC-1295 (DAC) sustains IGF-1 elevation for days. WADA-prohibited.

  2. Weeks 4–12

    Any body-composition or recovery changes are anecdotal; there are no trials of the combination.

Reported side effectsreported in literature

Reported in published literature and user reports. Not a complete list, and not medical advice.

  • Injection-site reactions (redness, itching, pain)
  • Flushing, headache, water retention
  • Elevated IGF-1 with prolonged use
  • Unstudied combined-injection safety

If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.

Cautionsdiscuss with a clinician
Use caution or avoid if
  • No human safety data exist for the blend; combined-injection safety is unstudied and research-use only.
  • As GH secretagogues, the combination raises GH/IGF-1 and may worsen glucose tolerance — a theoretical concern in diabetes or insulin resistance.
  • Elevated GH/IGF-1 raises a theoretical concern in the setting of active or prior malignancy.
Interactions
  • No documented human drug interactionsNo interaction studies of the combination; uncharacterized in humans (research use only)
  • Insulin and other glucose-lowering medicationsGrounded caution — GH secretagogues can raise blood glucose and reduce insulin sensitivity, theoretically opposing glycemic control

Compare

FAQ

Is the CJC-1295/Ipamorelin blend studied in clinical trials?

No. There are no human trials of the combination. Evidence comes from each component separately — small early-phase PK/PD studies for CJC-1295 and a phase 2 trial for ipamorelin that missed its primary endpoint. Any synergy is hypothesized, not demonstrated.

What is in this blend?

Two growth-hormone secretagogues — CJC-1295 (a GHRH-receptor agonist) and ipamorelin (a selective ghrelin/GHS-R1a agonist) — that stimulate pituitary GH release through complementary pathways.

Is it banned in sport?

Yes. GH-axis stimulants and their analogs are WADA-prohibited (class S2), so this blend is banned in sport at all times.

Why combine CJC-1295 with ipamorelin?

The two act on different receptors — CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin/GHS-R1a receptor — so co-stimulation is proposed to produce a larger, more physiologic GH pulse than either alone. The two-pathway rationale is mechanistically reasonable, but the specific combination has not been formally tested in controlled studies.

What is the difference between CJC-1295 with and without DAC?

DAC (Drug Affinity Complex) is a modification that binds CJC-1295 to albumin, extending its half-life so GH/IGF-1 stays elevated for days; the no-DAC form (often sold as modified GRF 1-29) is short-acting and clears within hours. Blends use one or the other, which changes dosing frequency. Neither version is FDA-approved, and the combination is research use only.

How does this differ from the Tesamorelin/Ipamorelin blend?

Both pair ipamorelin with a GHRH analog; the difference is the GHRH component. This blend uses CJC-1295, whereas the sibling uses tesamorelin — a stabilized GHRH analog that is FDA-approved on its own (as Egrifta) for HIV-associated lipodystrophy. Both blends are unstudied as combinations and both are WADA-prohibited (S2).

Similar compounds

Tesamorelin / IpamorelinBlendTesamorelin + Ipamorelin GH-support blend.CJC-1295 (No-DAC)Growth HormoneShort-acting GHRH analog (Mod GRF 1-29) studied for growth-hormone release; often paired with Ipamorelin.IpamorelinGrowth HormoneSelective GH secretagogue, often paired with CJC-1295.
Sources

Starting references for the library summary. These are not dosing instructions or medical advice.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsJournal of Clinical Endocrinology & Metabolismpubmed.ncbi.nlm.nih.gov/16352683/…Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsInternational Journal of Colorectal Diseasepubmed.ncbi.nlm.nih.gov/25331030/…Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinologypubmed.ncbi.nlm.nih.gov/9849822/…Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogJournal of Clinical Endocrinology & Metabolismpubmed.ncbi.nlm.nih.gov/17018654/…

For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.